Hikal, Pfizer Sign Agreement for API Supply
ePT--the Electronic Newsletter of Pharmaceutical Technology
Pfizer and Hikal signed a contract manufacturing agreement in which Hikal will supply active pharmaceutical ingredients.
Mumbai, India (Jan. 7)-Pfizer (New York) and Hikal signed a contract manufacturing agreement in which Hikal will supply active pharmaceutical ingredients. Terms of the agreement were not disclosed at press time.
“We are extremely pleased to be selected as a long-term contract manufacturer by Pfizer,” said Jai Hiremath, vice chairman and managing director of Hikal in a company statement. “This agreement will have a substantial impact on our pharmaceutical business in the coming years.”
“We look forward to working with Hikal, a respected contract manufacturing company and are delighted that they are able to contribute towards supply of APIs for Pfizer products,” said Peter Stevenson, vice-president, global contract manufacturing, procurement and Pfizer Center Source, Pfizer Inc., in a prepared statement.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
